New York, May 20, 2026, 13:02 (EDT)
NervGen Pharma Corp. was up almost 4% to $3.70 in midday Nasdaq trade Wednesday, lifted by its latest quarterly update as the company preps for its late-stage RESTORE trial. Shares moved between $3.58 and $3.75 and about 59,940 shares were traded.
NervGen is moving from lining up with regulators to actually starting work. The company said this week it’s got an agreement with the U.S. Food and Drug Administration on RESTORE, the registrational study of NVG-291 for chronic tetraplegia, where all four limbs are paralyzed. CEO Adam Rogers said NervGen is “firmly in execution mode.” Site activation has started, and the study is still on track to kick off in mid-2026. GlobeNewswire
The move leaves the stock with a better short-term setup, though challenges remain. For a small clinical-stage biotech, the key is less about quarterly loss numbers now. The next move will depend on starting RESTORE, securing funding, enrolling patients and getting data that works for both regulators and investors.
NervGen is set to get new data soon. The company said that biomechanical gait analysis from the independent, blinded CONNECT SCI study is still in progress, with results due in the second quarter. Reviewers don’t know whether patients got the drug or placebo, a move to cut down bias.
Balance sheet numbers are in focus. NervGen reported C$16.56 million in cash and cash equivalents at March 31 in its SEC management discussion. The company used C$8.20 million in cash for operations in the quarter. Management expects the current cash to last through Q2 2026 unless it cuts or delays spending. NervGen said it needs more capital to reach its objectives, which include the Phase 3 trial.
Chip names pulled Wall Street higher at midday, ahead of Nvidia’s numbers. The Nasdaq climbed roughly 1.4%. Major indexes traded in the green, Reuters said.
NervGen trades mainly on Nasdaq now. The stock started on Nasdaq as NGEN in January and the company later dropped its TSX Venture Exchange listing, saying the U.S. market would be the only venue for common shares and would cut overlapping expenses.
Spinal cord injury drug development has limited competition, though there are a few players. Lineage Cell Therapeutics is running a study of OPC1, an allogeneic oligodendrocyte progenitor cell therapy. The cells are meant to support or replace damaged spinal cord cells, targeting both subacute and chronic spinal cord injury. This approach is different from NervGen’s drug candidate.
NervGen’s data is getting some specialist attention, but the track record in this field is poor. In April, Armin Curt, clinical director of the Accelerated Translational Program at Wings for Life, called NVG-291 the “most compelling clinical evidence” he had seen so far for a pharmacologic treatment in chronic tetraplegia. He also pointed out the focus on hand function in the RESTORE study design. GlobeNewswire
FDA alignment doesn’t equal approval, and having a Phase 3 plan doesn’t solve funding. If the gait analysis misses, if RESTORE’s launch gets delayed, or if the company raises money at poor terms, Wednesday’s move could reverse in a hurry. Management has already cautioned that clinical plans still need more capital and trial risk is still a concern.
The stock has a shorter timeframe ahead. Data is due this quarter. The trial is set to begin by mid-year. Cash runway only stretches for months, not years.
